• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Scientific Media

  • GDE – “Scientific Media @Leaders in Pharmaceutical Business Intelligence (LPBI)”

  • http://pharmaceuticalintelligence.com/

HQS – Boston, MA

OUR CURRENT PLAN FOR FUNDING

GDE’s Scientific Media Business

We need a TOP Scientific e-Publisher to acquire

– the Journal and

– the BioMed Series

Alternatively, we need a FOUNDATION that Specializes in Funding Scientific Media or Communications to fund the Journal and the BioMed e-Series allowing to MARKET the e-Books to Cardiologists, Oncologist, in the U.S. and in Europe, explore the Market for Medical Books in Japan and China.

A.  Open Access online Scientific Journal  COVERS

We are seeking a Scientific Publisher to Publish the Journal in China and other countries in South East Asia

B.  BioMed e-Series

We are seeking a Scientific Publisher to Market our Amazon.com Medicine e-Books and Books to Cardiologists and Oncologists in CHINA

C.  Biotech and Medicine REAL TIME Press Coverage using Social Media and Tweet Analytics

We are seeking to scale up this Business to cover Conferences in Biotech and Medicine in South East Asia. We developed a methodology for REAL TIME conference coverage by Domain Experts

NEWS

10/22/2015 – 

#1: STARTEGY for the Journal

To follow up on ALL the FOUR NEEDS — we need a DEDICATED BD IN SHANGHAI

#1 – NEED for Introduction to George Institute for Global Health, China

#2  – NEED for Introduction to GEORGE CLINICAL, Australia, See e-mail, Anne Sim

LPBI the site and journal would fit perfectly. I suggest a personal agreement with them for regular interviews and postings on our site according to each individual expertise. This can and should be one on one with resultant site and tweet analytics as deliverables. Then indivual companies can work with GDE or M3DP

#3 – NEED for Introduction to Investment Funds in Healthcare in Shanghai

#4 – Medical 3D BioPrinting (M3DP) – A System Integration Start Up [3D Printer Sales, R&D Biologics, BioMed&Medical Devices]

NEED for Introduction to Private Equity INVESTOR(S) for Funding, Developing and Managing

@@@@@@@@@@@

#2: BASKET for GDE’s IT Issues

http://pharmaceuticalintelligence.com/2015/10/17/basket-for-gdes-it-issues/

@@@@@@@@@@@

  • Scientific Journal

http://pharmaceuticalintelligence.com/

On 9/23/2015

740,940 Readers

3,294 Scientific Articles

385 Categories of Research

7,106 Tags

NEWS

  • BioMed e-Series

10/22/2015

Our Director of Business Development for the Benelux and Scandinavian Counties, based in Amsterdam, Mr. Silvester Werring, has contacted on behalf of LPBI, the President of Elsevier.

Updates will follow.

Continue reading,

This e-mail is an example for

1. CONTINUOUS IMPROVEMENT procedures taking place at our BioMed e-Series

2. Collaborations among Editors Cross e-Series

3. Interaction among Editors and Editor-in-Chief

4. Parallel activities on “Marketing and Business Development” and “Editorial Development” for:

4.1 Series B: Volume one in Draft on Amazon ready for Upload, Volume Two in preliminary preparations

4.2 Series D – Decisions needed on Development, Beyond Volume 1 published in 2015 on Amazon.

4.2 Series A is Under Defined Plan – on going:

Dr. Pearlman will show progress on a Quarterly basis for FOUR Hard Copies in 2016.

4.3 Series C – Decisions PENDING on work beyond Volumes 1, published in 2015 on Amazon, and Volume 2, NOW in QA,

regarding Future of Volume 3, 4

4.4 Series E – Volume 1, Needs Editor and Development of eTOCs,

Two volumes have been completed by Dr. Larry.

Volume 4 on Medical 3D BioPrinting, Work-in-Progress

All Titles launched by Aviva.

http://pharmaceuticalintelligence.com/biomed-e-books/

Series E: Patient-Centered Medicine — e-Books Title Plan for 2015-2016

onepage series BCDE covers

This page has the following sub pages.

  • Work-in-Progress Volume One: The Patient’s Voice: Personal Experience with Invasive Medical Procedures
  • 90% DONE Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
  • READY for AMAZON Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
  • NEW TITLE Volume Four: Medical 3D BioPrinting – The Revolution in Medicine

Series C: Cancer Volume Two — Deadline PENDING for Dr. Sag and Dr. Raphael Nir

NEWS

  • Biotech and Medicine Conferences — REAL TIME Press Coverage using Social Media and Tweet Analytics

http://pharmaceuticalintelligence.com/2015/08/15/press-release-on-amazon-com-biomedical-e-books-e-series-by-the-team-of-leaders-in-pharmaceutical-business-intelligence-cardiovascular-genomics-cancer-biomed-patient-centered-medicine/

Forthcoming

The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Joseph B. Martin Conference Center of the Harvard New Research Building at Harvard Medical School

http://pharmaceuticalintelligence.com/2015/07/09/the-11th-annual-personalized-medicine-conference-november-18-19-2015-joseph-b-martin-conference-center-of-the-harvard-new-research-building-at-harvard-medical-school/

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,979 other subscribers

  • Recent Posts

    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
    • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
    • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
    • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
    • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
    • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
    • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
    • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
    • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
    • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    %d bloggers like this: